Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PLX2853 |
Synonyms | |
Therapy Description |
PLX2853 is a BET bromodomain inhibitor with specificity for BRD4, which may result in cell cycle arrest thereby inhibiting cell proliferation (PMID: 32717030). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PLX2853 | PLX-2853|PLX 2853 | BRD4 Inhibitor 10 | PLX2853 is a BET bromodomain inhibitor with specificity for BRD4, which may result in cell cycle arrest thereby inhibiting cell proliferation (PMID: 32717030). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03297424 | Phase Ib/II | PLX2853 | A Study of PLX2853 in Advanced Malignancies. | Completed | USA | 0 |
NCT03787498 | Phase I | PLX2853 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT04493619 | Phase Ib/II | Carboplatin + PLX2853 PLX2853 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Terminated | USA | CAN | 0 |